In re Bystolic Antitrust Litigation
Case Number:
1:20-cv-05735
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Alston & Bird
- A&O Shearman
- ArentFox Schiff
- Berger Montague
- Buchanan Ingersoll
- Cohen Milstein
- Dechert LLP
- DiCello Levitt
- Faruqi & Faruqi
- Garwin Gerstein
- Glancy Prongay
- Goodwin Procter
- Grant & Eisenhofer
- Hangley Aronchick
- Heim Payne
- Kenny Nachwalter
- Kirkland & Ellis
- Lewis & Llewellyn
- NastLaw
- Odom & Des Roches
- Orrick Herrington
- Smith Segura
- Steptoe LLP
- Tarter Krinsky
- Taus Cebulash
- White & Case
Companies
- AbbVie Inc.
- Albertsons Cos. Inc.
- Alkem Laboratories Ltd.
- Allergan PLC
- Amerigen Pharmaceuticals Ltd.
- Ascend Laboratories LLC
- CVS Health Corp.
- Forest Laboratories Inc.
- Fraternal Order of Police
- Glenmark Pharmaceuticals Ltd.
- Hetero Drugs Ltd.
- Hetero Labs Ltd.
- J.M. Smith Corp.
- New Civil Liberties Alliance
- Rite Aid Corp.
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- Torrent Pharmaceuticals Ltd.
- United Food & Commercial Workers International Union
Sectors & Industries:
-
March 24, 2023
Bystolic 'Side Deals' Deemed Legit, Not Generic Delay Plans
Drug wholesalers, retailers and employee benefit funds made none of the complaint changes they'd need to, to undermine the legitimacy of drug supply and development deals an AbbVie predecessor struck settling patent infringement litigation staving off generic versions of hypertension drug Bystolic, according to a ruling unsealed Friday.
-
January 24, 2022
Pharma Cos. Get Bystolic Generic Delay Claims Tossed
A New York federal judge dismissed claims brought against AbbVie and other pharmaceutical firms by direct purchasers including Walgreens and CVS as well as claims brought by end payers who accused the drugmakers of conspiring to keep generic forms of the blockbuster hypertension drug Bystolic off the market.
-
September 21, 2021
AbbVie Calls Retailers' Bystolic Generic Delay Claims Flawed
AbbVie has urged a New York federal judge to toss complaints from retailers CVS and Walgreens accusing the drugmaker of plotting to keep generic forms of the blockbuster drug Bystolic off the market.
-
February 09, 2021
AbbVie, Others Move To End Generic Bystolic Antitrust Claims
AbbVie Inc. and subsidiaries have fired back against a consolidated class action accusing the drug giant of reaping millions of dollars in profit by paying competitors to delay generic forms of the blood pressure drug Bystolic, arguing in a dismissal motion that some buyers lack standing to assert various state antitrust and consumer-protection claims.